Hansa Medical AB applies for listing of its shares on the main market of Nasdaq Stockholm. Hansa Medical AB’s share is publicly traded on NASDAQ First North since October 17, 2007. Hansa Medical AB has submitted a preliminary application have its shares listed on the main market of Nasdaq Stockholm. About IdeS IdeS, a unique molecule with a novel mechanism, is a bacterial enzyme that cleaves human IgG antibodies. IdeS degrades all IgG specifically, swiftly and efficiently. IdeS has been tested for safety and efficacy in numerous in vitro and in vivo models. During 2013, a Phase I clinical trial on 29 healthy subjects was conducted, demonstrating IdeS as efficacious and well tolerated with a favorable safety profile. During 2014 and 2015, a Phase II clinical trial in sensitized patients awaiting kidney transplantation has been conducted. Preliminary data shows that IdeS has very good efficacy in highly sensitized patients on the kidney transplant waitlist. The study shows that IdeS has the capacity to make sensitized patients eligible for transplantation by decreasing HLA antibodies to levels acceptable for transplantation. In addition to transplantation, IdeS has potential indications within a variety of rare autoimmune diseases including anti-GBM disease. IdeS is protected by several patents and has been published in numerous peer review journals. The information in this press release is disclosed pursuant to the Securities Markets Act or the Financial Instruments Trading Act. The information was released for public disclosure on February 12, 2015 at 16.00. For further information, please contact: Hansa Medical AB Fredrik Lindgren, President and CEO Mobile: 46 705 61 61 77 E-mail: fredrik.lindgren@hansamedical.com www.hansamedical.com About Hansa Medical AB Hansa Medical is a biopharmaceutical company focused on novel immunomodulatory enzymes. Lead project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Other projects include HBP (a market introduced diagnostic marker for severe sepsis) and EndoS (an antibody-modulating bacterial enzyme in pre-clinical development). The company is based in Lund, Sweden. Hansa Medical's share (HMED) is listed on NASDAQ First North in Stockholm with Remium Nordic AB as Certified Adviser. Major shareholders are Farstorps Gård AB and Nexttobe AB.
Hansa Medical AB applies for listing on Nasdaq Stockholm
Top 10 Most Recent News Articles
Faith and Resilience in China: The Legacy of the Long March
History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...
Continue Reading
Antheia Secures $80M for Critical Medicine Onshoring
Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...
Continue Reading
Lundbeck's Board Leadership Transitions into New Era
A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...
Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver
You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...
Continue Reading
AEVEX Faces 48-Hour Deadline for Investor Class Action
Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....
Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note
AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...
Continue Reading
UEG's New Advisory Board: Elevating Patient Voices
Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...
Continue ReadingTop 5 Most Recently Viewed Articles
CareDx and Dovetail Genomics Forge New Path in Transplant Solutions
Partnership to Enhance HLA Typing Technology CareDx, Inc. (NASDAQ: CDNA), renowned for its pioneering precision medicine approach for transplant patients, has recently joined forces with Dovetail Genomics, a recognized leader in genomic solutions. This notable collaboration is set to introduce an Early Access Program designed for HLA laboratories, leveraging a unique...
Continue Reading
Pet Valu Holdings Secures C$150 Million Through Secondary Offering
Pet Valu Holdings Hits Milestone with Recent Secondary Offering MARKHAM, Ontario — Pet Valu Holdings Ltd. (“Pet Valu” or the “Company”) (TSX: PET), a prominent name in Canadian specialty retailing, has unveiled the successful completion of its secondary bought deal offering. This initiative has generated an impressive C$150 million through the sale of 5,200,000...
Continue Reading
SMCP Settles Legal Proceedings Over 15.9% Stake Dispute
Overview of SMCP's Recent Legal Developments In a significant update, SMCP has received confirmation regarding the legal proceedings related to a notable 15.9% stake in its share capital. The London Court of Appeal has denied requests from Dynamic Treasure Group (DTG) to appeal the High Court's decision, which ruled the sale of shares to DTG as invalid. This ruling...
Continue Reading
Grit Real Estate Announces Important AGM Details for Shareholders
Grit Real Estate Income Group's Upcoming AGM Grit Real Estate Income Group Limited, a pan-African leader in real estate, has made a significant announcement regarding its forthcoming Annual General Meeting (AGM). This event is set to take place on a Friday, specifically at 14h30 Mauritian time. Although the exact location is specified, the company invites all eligible...
Continue Reading
Petaluma Enriches Pet Nutrition with Dr. Sarah Dodd
Petaluma Welcomes Dr. Sarah Dodd as Advisor and Formulator Petaluma, a forward-thinking sustainable pet nutrition company, is excited to announce the addition of Dr. Sarah Dodd as an Advisor and Formulator. Dr. Dodd is a renowned figure in the field of plant-based pet nutrition, bringing with her a wealth of experience to transform pet food for a sustainable and humane...
Continue Reading